Immune cells Re-Trained to fight Drug-Resistant ovarian cancer

NCT ID NCT01883297

Ongoing Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This early-phase trial investigates whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), can be re-stimulated in the lab and infused back to fight platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Participants receive their re-activated TILs along with low-dose interleukin-2 (IL-2) to support immune activity. The main goal is to assess safety and side effects, while also looking for signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: re-stimulated tumor-infiltrating lymphocytes (TILs) plus low-dose interleukin-2 (IL-2)
What this could lead to: If it works, this approach could offer a new treatment option for patients with platinum-resistant ovarian cancer, potentially controlling the disease where standard therapies have failed.
What could go wrong: This is a very early phase I trial with only a small number of participants, so safety and effectiveness are not yet established. Side effects from the cell infusion and IL-2 therapy may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CANCER HIGH GRADE SEROUS OVARIAN CANCER PLATINUM-RESISTANT PRIMARY PERITONEAL CANCER RECURRENT

Contacts and locations

Show contact details

Locations

Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.